Alkermes Restructures, Prioritizing CNS And Oncology And Cutting 160 Employees

 
• By Jessica Merrill

The reorganization, which is expected to save $150m, will cement the company's transition from a drug delivery specialist to a drug developer, CEO Richard Pops said.

man hand holding card with the word expenses. cutting expenses and costs concept. retro style image - Image
Alkermes expects to save $150m from a reorganization • Source: Shutterstock

More from Strategy

More from Business